LGND- Ligand Pharmaceuticals Inc
Classified under Biotechnology (Health Care sector), LGND's insider flows are most useful compared with peers in the same group.
Insider Ownership
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 161.3K | $46.90M | - | |
| Dir | 43.7K | $12.70M | - | |
| CFO | 28.6K | $8.31M | - | |
| Dir | 11.7K | $3.39M | - | |
| Dir | 4.4K | $1.29M | - |
Activity
Buys and sells only
Transactions
10 filings
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 2, 2026 | Kozarich John W55 | Director | Sell | 467 | $189.58 | $88,532.49 | -0.2% | +5.0% | - | |
| Dec 12, 2025 | Espinoza Octavio48 | Chief Financial Officer | Sell | 1,804 | $188.31 | $339,711.24 | -6.4% | +11.6% | - | |
| Dec 1, 2025 | Kozarich John W55 | Director | Sell | 467 | $195.84 | $91,456.89 | -0.2% | +2.8% | - | |
| Nov 7, 2025 | Lamattina John L | Director | Sale+OE | 4,179 | $205.45 | $858,575.55 | -6.4% | -5.3% | - | |
| Nov 7, 2025 | Gray Nancy Ryan | Director | Sale+OE | 6,571 | $205.45 | $1,350,011.95 | -28.9% | -5.3% | - | |
| Nov 3, 2025 | Kozarich John W55 | Director | Sell | 467 | $191.05 | $89,219.01 | -0.3% | +3.5% | - | |
| Oct 1, 2025 | Kozarich John W55 | Director | Sell | 467 | $179.44 | $83,800.34 | -0.3% | +6.2% | - | |
| Sep 23, 2025 | Aryeh Jason | Director | Sell | 10,000 | $170.81 | $1,708,087.72 | -4.5% | +16.0% | - | |
| Sep 2, 2025 | Kozarich John W55 | Director | Sell | 467 | $162.26 | $75,774.85 | -0.3% | +20.3% | - | |
| Aug 1, 2025 | Kozarich John W55 | Director | Sell | 467 | $131.88 | $61,585.86 | -1.0% | +40.9% | +116.7% |
Page 1Next →